Crohn's disease Trials in Paris, France
Conditions / Crohn's disease / Paris, France
Clinical trials for Crohn's disease investigate a range of treatment strategies and patient populations.
77 total trials for this combination
Showing top 10 of 77 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06548542 | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease | RECRUITING | PHASE2 |
| NCT01369329 | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) | COMPLETED | PHASE3 |
| NCT03279081 | Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) | COMPLETED | PHASE3 |
| NCT03926130 | A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | COMPLETED | PHASE3 |
| NCT00771667 | A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy | COMPLETED | PHASE2 |
| NCT05242471 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03466411 | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT01369342 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) | COMPLETED | PHASE3 |
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) | RECRUITING | — |
| NCT01369355 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) | COMPLETED | PHASE3 |